WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Ownership - Who owns Ultragenyx Pharmaceutical?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Ultragenyx Pharmaceutical Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Howard HornChief Financial Officer2025-10-137,942$31.51
$250.25kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2025-09-1864$29.17
$1.87kSell
Karah Herdman ParschauerEVP and Chief Legal Officer2025-09-122,450$31.17
$76.37kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2025-09-0584$31.39
$2.64kSell
Corazon Corsee D. SandersDirector2025-06-202,405$37.39
$89.92kSell
Eric CrombezEVP and Chief Medical Officer2025-05-05520$39.24
$20.40kSell
Eric CrombezEVP and Chief Medical Officer2025-04-21242$35.11
$8.50kSell
Howard HornChief Financial Officer2025-03-061,785$40.40
$72.11kSell
Eric CrombezEVP and Chief Medical Officer2025-03-038,945$42.10
$376.58kSell
Erik HarrisEVP Chief Commercial Officer2025-03-0315,103$42.10
$635.84kSell

1 of 3

RARE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RARE insiders and whales buy or sell their stock.

RARE Shareholders

What type of owners hold Ultragenyx Pharmaceutical Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc10.60%10,213,422$325.50MInstitution
Emil D. Kakkis7.56%7,288,686$232.29MInsider
Blackrock Inc6.49%6,256,145$199.38MInstitution
Fmr LLC4.90%4,718,234$150.37MInsider
Sands Capital Management LLC4.09%3,943,485$125.68MInstitution
Jpmorgan Chase Co3.38%3,260,868$103.92MInstitution
Price T Rowe Associates Inc2.99%2,886,268$91.99MInstitution
Baker Bros Advisors LP2.88%2,772,692$88.37MInstitution
Fmr LLC2.70%2,604,588$83.01MInstitution
Tpg Group Holdings Sbs Advisors Inc2.69%2,596,420$82.75MInsider

1 of 3

RARE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RARE85.46%14.54%Net SellingNet Selling
IRON57.71%42.29%Net SellingNet Selling
CNTA89.96%10.04%Net SellingNet Selling
TVTX63.44%36.56%Net SellingNet Selling
XENE97.09%2.91%Net BuyingNet Buying
View Top Biotech Stocks

Ultragenyx Pharmaceutical Stock Ownership FAQ

Who owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ: RARE) is owned by 97.67% institutional shareholders, 16.62% Ultragenyx Pharmaceutical insiders, and 0.00% retail investors. Emil D. Kakkis is the largest individual Ultragenyx Pharmaceutical shareholder, owning 7.29M shares representing 7.56% of the company. Emil D. Kakkis's Ultragenyx Pharmaceutical shares are currently valued at $232.29M.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.